Alzheimer’s Disease Diagnostics Market Analysis and Global Forecast 2023-2033
Price range: $ 1,390.00 through $ 5,520.00
Alzheimers Disease Diagnostics Market Research Report: By Type (Nervous System, Examination, Genetic Testing, Minor Mental State Examination, Brain Imaging), By Diagnostic Test (Genetic Testing, Positron Emission Tomography, Electroencephalography, Magnetic Resonance Imaging, Computed Tomography, Neurological Exam, Mini-mental State Exam (MMSE), Brain Imaging, Others), By End User (Clinics, Hospitals, Diagnostic Centers, Pharmaceutical Companies, Academic Research Center), and by Region — Forecast till 2033
Alzheimers Disease Diagnostics Market Overview
The Alzheimer’s Disease Diagnostics Market Size is expected to reach USD 7.15 Billion by 2033. The Alzheimers Disease Diagnostics industry size accounted for USD 4.14 Billion in 2023 and is expected to expand at a compound annual growth rate (CAGR) of 8.90% from 2023 to 2033. Alzheimer’s disease diagnostics involves a comprehensive process of assessing and evaluating an individual’s cognitive abilities, memory, behavior, and functional abilities to determine the presence and progression of Alzheimer’s disease. Diagnostic tools may include cognitive tests, brain imaging (such as MRI or PET scans), medical history evaluations, and assessments of daily living activities. Clinicians use these tools to differentiate Alzheimer’s disease from other types of dementia and identify characteristic changes in the brain, such as the presence of amyloid plaques and tau tangles. Early and accurate diagnosis is crucial for initiating appropriate interventions and providing support to individuals and their families facing the challenges of this neurodegenerative disorder.
Global Alzheimers Disease Diagnostics Market Synopsis
COVID-19 Impact Analysis
The COVID-19 pandemic had a profound and lasting impact on the Alzheimer’s Disease Diagnostics market. While the immediate focus of healthcare resources shifted towards addressing the pandemic, routine healthcare services, including Alzheimer’s diagnostics, faced disruptions. Access to healthcare facilities, diagnostic centers, and medical professionals were limited due to lockdowns, travel restrictions, and safety concerns, leading to delayed or deferred diagnoses for many individuals with Alzheimer’s disease. Additionally, the pandemic’s economic repercussions and redirected research efforts may have slowed down the development and adoption of innovative diagnostic technologies and treatments for Alzheimer’s disease. As the healthcare system adapts to post-pandemic challenges, efforts to enhance Alzheimer’s diagnostics and patient care are likely to regain momentum, but it may take time to fully recover from the pandemic’s impact on this critical area of healthcare.
Global Alzheimer’s Disease Diagnostics Market Dynamics
The major factors that have impacted the growth of Alzheimer’s Disease Diagnostics are as follows:
Drivers:
Aging Population and Increasing Disease Prevalence
The global population is aging, leading to a higher incidence of Alzheimer’s disease. As people live longer, the risk of developing the condition increases, driving the demand for Alzheimer’s disease diagnostics. The growing awareness of the disease and the importance of early detection also contribute to increased diagnostic testing.
Restraint:
- Limited Treatment Options
There is no cure for Alzheimer’s disease, and available treatments focus on managing symptoms rather than halting or reversing the disease’s progression. The lack of definitive treatment options may discourage investment in Alzheimer’s diagnostics, as some stakeholders may perceive limited opportunities for financial returns in this area.
Opportunity:
    Advancements in Biomarker Research
Researchers have made significant progress in identifying biomarkers associated with Alzheimer’s disease, such as amyloid and tau proteins. These biomarkers have the potential to revolutionize Alzheimer’s diagnostics, allowing for earlier and more accurate detection of the disease. As biomarker research continues to advance, there is an opportunity to develop novel diagnostic tests that can improve patient outcomes and support the development of targeted therapies.
Alzheimers Disease Diagnostics Market Segment Overview
By Type
Based on the Type, the market is segmented based on Nervous System, Examination, Genetic Testing, Minor Mental State Examination, and Brain Imaging. The Nervous System segment was projected to hold the largest market share in the Alzheimer’s Disease Diagnostics market due to its central role in the disease’s pathology and diagnostic methods.
By Diagnostic Test
Based on the Diagnostic Test, the market has been divided into Genetic Testing, Positron Emission Tomography, Electroencephalography, Magnetic Resonance Imaging, Computed Tomography, Neurological Exam, Mini-mental State Exam (MMSE), Brain Imaging, and Others. The Genetic Testing segment is expected to hold the largest market share in the Alzheimer’s Disease Diagnostics market due to its potential to identify genetic risk factors and facilitate early detection and personalized treatment approaches.
By End User
Based on End Users, the market has been divided into Clinics, Hospitals, Diagnostic Centers, Pharmaceutical Companies, and Academic Research Centers. The Clinics segment is expected to hold the largest market share in the Alzheimer’s Disease Diagnostics market due to its accessibility, as clinics play a vital role in providing diagnostic services and patient care.
Global Alzheimers Disease Diagnostics Market Regional Analysis
Based on region, the market has been divided into North America, Europe, Asia-Pacific, the Middle East & Africa, and Latin America. The area of North America is anticipated to dominate the market for the usage of Alzheimers Disease Diagnostics, followed by those in Asia-Pacific and Europe.
North America Market
North America has consistently maintained a significant market share in the Alzheimer’s Disease Diagnostics market due to several factors. First, the region has a large aging population, which increases the prevalence of Alzheimer’s disease, driving the demand for diagnostic services. Second, North America has a well-established and advanced healthcare infrastructure, with numerous diagnostic centers, research facilities, and specialized clinics dedicated to Alzheimer’s disease diagnosis and treatment. Third, extensive public and private investments in research and development, coupled with a supportive regulatory environment, have fostered the development and adoption of innovative diagnostic technologies. Additionally, the region’s high healthcare expenditure and increasing awareness of the importance of early diagnosis have further contributed to North America’s dominant position in the Alzheimer’s Disease Diagnostics market.
Asia Pacific Market
The Asia-Pacific region was experiencing significant growth and transDiagnostic Testation. The region’s rapidly aging population, increasing prevalence of Alzheimer’s disease, and improved healthcare infrastructure have collectively fueled the demand for advanced diagnostic tools and services. Governments and healthcare organizations have been actively promoting awareness campaigns and research initiatives to enhance early detection and management of the disease. Additionally, ongoing investments in research and development have led to the emergence of innovative diagnostic technologies, including biomarker-based tests and neuroimaging techniques. Despite these positive developments, challenges such as varying healthcare systems and economic disparities across the region have also influenced the accessibility and adoption of Alzheimer’s diagnostics.
Competitive Landscape
The competitive landscape includes key players (tier 1, tier 2, and local) having a presence across the globe. Companies such as F. Hoffmann-La Roche, Bristol-Myers Squibb, AstraZeneca PLC, Corium Inc, and Eisai Co. Ltd are some of the leading players in the global  Alzheimers Disease Diagnostics Industry. These players have adopted partnership, acquisition, expansion, and new product development, among others as their key strategies.
Key Market Players:
- Hoffmann-La Roche
- Bristol-Myers Squibb
- AstraZeneca PLC
- Corium Inc
- Eisai Co. Ltd
- Biogen Inc
- Johnson & Johnson
- Eli Lilly and Company
- Lupin Limited
- AbbVie Inc
Key development:
In October 2022, Cyclo Therapeutics, Inc. announced the initiation of its Phase 2b clinical trial for Trappsol Cyclo, aiming to address Alzheimer’s disease by targeting the reduction of amyloid beta and tau. The study received approval from the Institutional Review Board (IRB).
In September 2022, Esai Co Ltd and Biogen Inc. released encouraging topline results from Eisai’s large-scale global Phase 3 confirmatory Clarity AD clinical trial of lecanemab, an investigational anti-amyloid beta (Aβ) protofibril antibody. The trial focused on treating mild cognitive impairment (MCI) due to Alzheimer’s disease and mild Alzheimer’s disease.
Scope of the Report
Global Alzheimers Disease Diagnostics Market, by Type
- Nervous System
- Examination
- Genetic Testing
- Minor Mental State Examination
- Brain Imaging
Global Alzheimers Disease Diagnostics Market, by Diagnostic Test
- Genetic Testing
- Positron Emission Tomography
- Electroencephalography
- Magnetic Resonance Imaging
- Computed Tomography
- Neurological Exam
- Mini-mental State Exam (MMSE)
- Brain Imaging
- Others
Global Alzheimers Disease Diagnostics Market, by End User
- Clinics
- Hospitals
- Diagnostic Centers
- Pharmaceutical Companies
- Academic Research Center
Global Alzheimers Disease Diagnostics Market, by Region
- North America
- US
- Canada
- Mexico
- Europe
- UK
- Germany
- France
- Italy
- Spain
- Benelux
- Nordic
- Rest of Europe
- Asia Pacific
- China
- Japan
- South Korea
- Indonesia
- Austalia
- Malaysia
- India
- Rest of Asia Pacific
- South America
- Brazil
- Argentina
- Rest of South America
- Middle East & Africa
- Saudi Arabia
- UAE
- Egypt
- South Africa
- Rest of Middle East & Africa
| Parameters | Indicators |
|---|---|
| Market Size | 2033: $7.15 Billion |
| CAGR | 8.90% CAGR (2023-2033) |
| Base year | 2022 |
| Forecast Period | 2023-2033 |
| Historical Data | 2021 |
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| Key Segmentations | Type, Diagnostic Test, End User |
| Geographies Covered | North America, Europe, Asia-Pacific, Latin America, Middle East, Africa |
| Key Vendors | F. Hoffmann-La Roche, Bristol-Myers Squibb, AstraZeneca PLC, Corium Inc, Eisai Co. Ltd, Biogen Inc, Johnson & Johnson, Eli Lilly and Company, Lupin Limited, AbbVie Inc |
| Key Market Opportunities | • Advancements in biomarker research for early and accurate diagnosis |
| Key Market Drivers | • A growing aging population and increasing disease prevalence |
REPORT CONTENT BRIEF:
- High-level analysis of the current and future Alzheimers Disease Diagnostics Industry trends and opportunities
- Detailed analysis of current market drivers, restraining factors, and opportunities analysis in the future
- Historical market size for the year 2021, and forecast from 2023 to 2033
- Alzheimers Disease Diagnostics market share analysis for each segment
- Competitor analysis with a comprehensive insight into its product segment, financial strength, and strategies adopted.
- Identifies key strategies adopted by the key players including new product development, mergers and acquisitions, joint ventures, collaborations, and partnerships.
- To identify and understand the various factors involved in the global Alzheimers Disease Diagnostics market affected by the pandemic
- To provide year-on-year growth from 2022 to 2033
- To provide short-term, long-term, and overall CAGR comparison from 2022 to 2033.
- Provide Total Addressable Market (TAM) for the Global Alzheimers Disease Diagnostics Market.
Press Release
Global Pharmaceutical Manufacturing Market to Reach $1.38 Trillion by 2035 with 7.35% CAGR, New Research Shows
The Global Mammography Market Is Estimated To Record a CAGR of Around 10.29% During The Forecast Period
Glue Stick Market to Reach USD 2.35 Billion by 2034
Podiatry Service Market to Reach USD 11.88 Billion by 2034
Microfluidics Technology Market to Reach USD 32.58 Billion by 2034
Ferric Chloride Market to Reach USD 10.65 Billion by 2034
Family Practice EMR Software Market to Reach USD 21.52 Billion by 2034
Electric Hairbrush Market to Reach USD 15.95 Billion by 2034
Daily Bamboo Products Market to Reach USD 143.52 Billion by 2034
Cross-border E-commerce Logistics Market to Reach USD 112.65 Billion by 2034
Frequently Asked Questions (FAQ)
What are the 10 Years CAGR (2023 to 2033) of the global Alzheimers Disease Diagnostics market?
The global Alzheimers Disease Diagnostics market is growing at a CAGR of ~90% over the next 10 years
Which region has the highest growth rate in the market of Alzheimers Disease Diagnostics?
Asia Pacific is expected to register the highest CAGR during 2023-2033
Which region accounted for the largest share of the market of Alzheimers Disease Diagnostics?
North America holds the largest share in 2022
Major Key Players in the Market of Alzheimers Disease Diagnostics Manufacturers?
Hoffmann-La Roche, Bristol-Myers Squibb, AstraZeneca PLC, Corium Inc, Eisai Co. Ltd, Biogen Inc, Johnson & Johnson, Eli Lilly and Company, Lupin Limited, AbbVie Inc.
Do you offer Post Sale Support?
Yes, we offer 16 hours of analyst support to solve the queries
Do you deliver sections of a report?
Yes, we do provide regional as well as country-level reports. Other than this we also provide a sectional report. Please get in contact with our sales representatives.
Table of Content
CHAPTER 1. Executive Summary CHAPTER 2. Scope of the Study 2.1. Market Definition 2.2. Market Scope & Segmentation 2.2.1. Objective of Report CHAPTER 3. Evolve BI Methodology 3.1. Data Collection & Validation Approach 3.2. Market Size Estimation and Forecast CHAPTER 4. Exclusive Analysis 4.1. Market Opportunity Score 4.1.1. Type Segement – Market Opportunity Score 4.1.2. Diagnostic Test Segment – Market Opportunity Score 4.1.3. End User Segment – Market Opportunity Score 4.2. Key Market Influencing Indicators CHAPTER 5. Market Insights and Trends 5.1. Value Chain Analysis 5.1.1. Raw Material 5.1.2. Manufacturing Process 5.1.3. Distribution Channel 5.1.4. End User 5.2. Porter’s Five Forces Analysis 5.2.1. Bargaining Power of Buyers 5.2.2. Bargaining Power of Suppliers 5.2.3. Threat of New Entrant 5.2.4. Threat of Substitute 5.2.5. Industry Rivalry 5.3. COVID-19 Impact and Post COVID Scenario on Alzheimers Disease Diagnostics Market 5.3.1. Impact of COVID-19 5.3.2. Government Support and Industry Revival Policies 5.3.3. Measures Taken by Companies to Mitigate Negative Impact 5.3.4. Post COVID Trend CHAPTER 6. MArket Dynamics 6.1. Introduction 6.2. Drivers 6.2.1. Driver 1 6.2.2. Driver 2 6.2.3. Driver 3 6.3. Restraints 6.3.1. Restraint 1 6.3.2. Restraint 2 6.4. Opportunity 6.4.1. Opportunity 1 CHAPTER 7. Global Alzheimers Disease Diagnostics Market, By Type 7.1. Introduction 7.1.1. Nervous System 7.1.2. Examination 7.1.3. Genetic Testing 7.1.4. Minor Mental State Examination 7.1.5. Brain Imaging CHAPTER 8. Global Alzheimers Disease Diagnostics Market, By Diagnostic Test 8.1. Introduction 8.1.1. Genetic Testing 8.1.2. Positron Emission Tomography 8.1.3. Electroencephalography 8.1.4. Magnetic Resonance Imaging 8.1.5. Computed Tomography 8.1.6. Neurological Exam 8.1.7. Mini-mental State Exam (MMSE) 8.1.8. Brain Imaging 8.1.9. Others CHAPTER 9. Global Alzheimers Disease Diagnostics Market, By End User 9.1. Introduction 9.1.1. Clinics 9.1.2. Hospitals 9.1.3. Diagnostic Centers 9.1.4. Pharmaceutical Companies 9.1.5. Academic Research Center CHAPTER 10. Global Alzheimers Disease Diagnostics Market, By Region 10.1. Introduction 10.2. NORTH AMERICA 10.2.1. North America: Market Size and Forecast, By Country, 2023 – 2033 ($ Million) 10.2.2. North America: Market Size and Forecast, By Type, 2023 – 2033 ($ Million) 10.2.3. North America: Market Size and Forecast, By Diagnostic Test, 2023 – 2033 ($ Million) 10.2.4. North America: Market Size and Forecast, By End User, 2023 – 2033 ($ Million) 10.2.5. US 10.2.5.1. US: Market Size and Forecast, By Type, 2023 – 2033 ($ Million) 10.2.5.2. US: Market Size and Forecast, By Diagnostic Test, 2023 – 2033 ($ Million) 10.2.5.3. US: Market Size and Forecast, By End User, 2023 – 2033 ($ Million) 10.2.6. CANADA 10.2.6.1. Canada: Market Size and Forecast, By Type, 2023 – 2033 ($ Million) 10.2.6.2. Canada: Market Size and Forecast, By Diagnostic Test, 2023 – 2033 ($ Million) 10.2.6.3. Canada: Market Size and Forecast, By End User, 2023 – 2033 ($ Million) 10.2.7. MEXICO 10.2.7.1. Mexico: Market Size and Forecast, By Type, 2023 – 2033 ($ Million) 10.2.7.2. Mexico: Market Size and Forecast, By Diagnostic Test, 2023 – 2033 ($ Million) 10.2.7.3. Mexico: Market Size and Forecast, By End User, 2023 – 2033 ($ Million) 10.3. Europe 10.3.1. Europe: Market Size and Forecast, By Country, 2023 – 2033 ($ Million) 10.3.2. Europe: Market Size and Forecast, By Type, 2023 – 2033 ($ Million) 10.3.3. Europe: Market Size and Forecast, By Diagnostic Test, 2023 – 2033 ($ Million) 10.3.4. Europe: Market Size and Forecast, By End User, 2023 – 2033 ($ Million) 10.3.5. U.K. 10.3.5.1. U.K.: Market Size and Forecast, By Type, 2023 – 2033 ($ Million) 10.3.5.2. U.K.: Market Size and Forecast, By Diagnostic Test, 2023 – 2033 ($ Million) 10.3.5.3. U.K.: Market Size and Forecast, By End User, 2023 – 2033 ($ Million) 10.3.6. GERMANY 10.3.6.1. Germany: Market Size and Forecast, By Type, 2023 – 2033 ($ Million) 10.3.6.2. Germany: Market Size and Forecast, By Diagnostic Test, 2023 – 2033 ($ Million) 10.3.6.3. Germany: Market Size and Forecast, By End User, 2023 – 2033 ($ Million) 10.3.7. FRANCE 10.3.7.1. France: Market Size and Forecast, By Type, 2023 – 2033 ($ Million) 10.3.7.2. France: Market Size and Forecast, By Diagnostic Test, 2023 – 2033 ($ Million) 10.3.7.3. France: Market Size and Forecast, By End User, 2023 – 2033 ($ Million) 10.3.8. ITALY 10.3.8.1. Italy: Market Size and Forecast, By Type, 2023 – 2033 ($ Million) 10.3.8.2. Italy: Market Size and Forecast, By Diagnostic Test, 2023 – 2033 ($ Million) 10.3.8.3. Italy: Market Size and Forecast, By End User, 2023 – 2033 ($ Million) 10.3.9. SPAIN 10.3.9.1. Spain: Market Size and Forecast, By Type, 2023 – 2033 ($ Million) 10.3.9.2. Spain: Market Size and Forecast, By Diagnostic Test, 2023 – 2033 ($ Million) 10.3.9.3. Spain: Market Size and Forecast, By End User, 2023 – 2033 ($ Million) 10.3.10. BENELUX 10.3.10.1. BeNeLux: Market Size and Forecast, By Type, 2023 – 2033 ($ Million) 10.3.10.2. BeNeLux: Market Size and Forecast, By Diagnostic Test, 2023 – 2033 ($ Million) 10.3.10.3. BeNeLux: Market Size and Forecast, By End User, 2023 – 2033 ($ Million) 10.3.11. RUSSIA 10.3.11.1. Russia: Market Size and Forecast, By Type, 2023 – 2033 ($ Million) 10.3.11.2. Russia: Market Size and Forecast, By Diagnostic Test, 2023 – 2033 ($ Million) 10.3.11.3. Russia: Market Size and Forecast, By End User, 2023 – 2033 ($ Million) 10.3.12. REST OF EUROPE 10.3.12.1. Rest of Europe: Market Size and Forecast, By Type, 2023 – 2033 ($ Million) 10.3.12.2. Rest of Europe: Market Size and Forecast, By Diagnostic Test, 2023 – 2033 ($ Million) 10.3.12.3. Rest of Europe: Market Size and Forecast, By End User, 2023 – 2033 ($ Million) 10.4. Asia Pacific 10.4.1. Asia Pacific: Market Size and Forecast, By Country, 2023 – 2033 ($ Million) 10.4.2. Asia Pacific: Market Size and Forecast, By Type, 2023 – 2033 ($ Million) 10.4.3. Asia Pacific: Market Size and Forecast, By Diagnostic Test, 2023 – 2033 ($ Million) 10.4.4. Asia Pacific: Market Size and Forecast, By End User, 2023 – 2033 ($ Million) 10.4.5. CHINA 10.4.5.1. China: Market Size and Forecast, By Type, 2023 – 2033 ($ Million) 10.4.5.2. China: Market Size and Forecast, By Diagnostic Test, 2023 – 2033 ($ Million) 10.4.5.3. China: Market Size and Forecast, By End User, 2023 – 2033 ($ Million) 10.4.6. JAPAN 10.4.6.1. Japan: Market Size and Forecast, By Type, 2023 – 2033 ($ Million) 10.4.6.2. Japan: Market Size and Forecast, By Diagnostic Test, 2023 – 2033 ($ Million) 10.4.6.3. Japan: Market Size and Forecast, By End User, 2023 – 2033 ($ Million) 10.4.7. INDIA 10.4.7.1. India: Market Size and Forecast, By Type, 2023 – 2033 ($ Million) 10.4.7.2. India: Market Size and Forecast, By Diagnostic Test, 2023 – 2033 ($ Million) 10.4.7.3. India: Market Size and Forecast, By End User, 2023 – 2033 ($ Million) 10.4.8. SOUTH KOREA 10.4.8.1. South Korea: Market Size and Forecast, By Type, 2023 – 2033 ($ Million) 10.4.8.2. South Korea: Market Size and Forecast, By Diagnostic Test, 2023 – 2033 ($ Million) 10.4.8.3. South Korea: Market Size and Forecast, By End User, 2023 – 2033 ($ Million) 10.4.9. THAILAND 10.4.9.1. Thailand: Market Size and Forecast, By Type, 2023 – 2033 ($ Million) 10.4.9.2. Thailand: Market Size and Forecast, By Diagnostic Test, 2023 – 2033 ($ Million) 10.4.9.3. Thailand: Market Size and Forecast, By End User, 2023 – 2033 ($ Million) 10.4.10. INDONESIA 10.4.10.1. Indonesia: Market Size and Forecast, By Type, 2023 – 2033 ($ Million) 10.4.10.2. Indonesia: Market Size and Forecast, By Diagnostic Test, 2023 – 2033 ($ Million) 10.4.10.3. Indonesia: Market Size and Forecast, By End User, 2023 – 2033 ($ Million) 10.4.11. MALAYSIA 10.4.11.1. Malaysia: Market Size and Forecast, By Type, 2023 – 2033 ($ Million) 10.4.11.2. Malaysia: Market Size and Forecast, By Diagnostic Test, 2023 – 2033 ($ Million) 10.4.11.3. Malaysia: Market Size and Forecast, By End User, 2023 – 2033 ($ Million) 10.4.12. AUSTRALIA 10.4.12.1. Australia: Market Size and Forecast, By Type, 2023 – 2033 ($ Million) 10.4.12.2. Australia: Market Size and Forecast, By Diagnostic Test, 2023 – 2033 ($ Million) 10.4.12.3. Australia: Market Size and Forecast, By End User, 2023 – 2033 ($ Million) 10.4.13. REST FO ASIA PACIFIC 10.4.13.1. Rest fo Asia Pacific: Market Size and Forecast, By Type, 2023 – 2033 ($ Million) 10.4.13.2. Rest fo Asia Pacific: Market Size and Forecast, By Diagnostic Test, 2023 – 2033 ($ Million) 10.4.13.3. Rest fo Asia Pacific: Market Size and Forecast, By End User, 2023 – 2033 ($ Million) 10.5. South America 10.5.1. South America: Market Size and Forecast, By Country, 2023 – 2033 ($ Million) 10.5.2. South America: Market Size and Forecast, By Type, 2023 – 2033 ($ Million) 10.5.3. South America: Market Size and Forecast, By Diagnostic Test, 2023 – 2033 ($ Million) 10.5.4. South America: Market Size and Forecast, By End User, 2023 – 2033 ($ Million) 10.5.5. BRAZIL 10.5.5.1. Brazil: Market Size and Forecast, By Type, 2023 – 2033 ($ Million) 10.5.5.2. Brazil: Market Size and Forecast, By Diagnostic Test, 2023 – 2033 ($ Million) 10.5.5.3. Brazil: Market Size and Forecast, By End User, 2023 – 2033 ($ Million) 10.5.6. ARGENTINA 10.5.6.1. Argentina: Market Size and Forecast, By Type, 2023 – 2033 ($ Million) 10.5.6.2. Argentina: Market Size and Forecast, By Diagnostic Test, 2023 – 2033 ($ Million) 10.5.6.3. Argentina: Market Size and Forecast, By End User, 2023 – 2033 ($ Million) 10.5.7. REST OF SOUTH AMERICA 10.5.7.1. Rest of South America: Market Size and Forecast, By Type, 2023 – 2033 ($ Million) 10.5.7.2. Rest of South America: Market Size and Forecast, By Diagnostic Test, 2023 – 2033 ($ Million) 10.5.7.3. Rest of South America: Market Size and Forecast, By End User, 2023 – 2033 ($ Million) 10.6. Middle East & Africa 10.6.1. Middle East & Africa: Market Size and Forecast, By Country, 2023 – 2033 ($ Million) 10.6.2. Middle East & Africa: Market Size and Forecast, By Type, 2023 – 2033 ($ Million) 10.6.3. Middle East & Africa: Market Size and Forecast, By Diagnostic Test, 2023 – 2033 ($ Million) 10.6.4. Middle East & Africa: Market Size and Forecast, By End User, 2023 – 2033 ($ Million) 10.6.5. SAUDI ARABIA 10.6.5.1. Saudi Arabia: Market Size and Forecast, By Type, 2023 – 2033 ($ Million) 10.6.5.2. Saudi Arabia: Market Size and Forecast, By Diagnostic Test, 2023 – 2033 ($ Million) 10.6.5.3. Saudi Arabia: Market Size and Forecast, By End User, 2023 – 2033 ($ Million) 10.6.6. UAE 10.6.6.1. UAE: Market Size and Forecast, By Type, 2023 – 2033 ($ Million) 10.6.6.2. UAE: Market Size and Forecast, By Diagnostic Test, 2023 – 2033 ($ Million) 10.6.6.3. UAE: Market Size and Forecast, By End User, 2023 – 2033 ($ Million) 10.6.7. EGYPT 10.6.7.1. Egypt: Market Size and Forecast, By Type, 2023 – 2033 ($ Million) 10.6.7.2. Egypt: Market Size and Forecast, By Diagnostic Test, 2023 – 2033 ($ Million) 10.6.7.3. Egypt: Market Size and Forecast, By End User, 2023 – 2033 ($ Million) 10.6.8. SOUTH AFRICA 10.6.8.1. South Africa: Market Size and Forecast, By Type, 2023 – 2033 ($ Million) 10.6.8.2. South Africa: Market Size and Forecast, By Diagnostic Test, 2023 – 2033 ($ Million) 10.6.8.3. South Africa: Market Size and Forecast, By End User, 2023 – 2033 ($ Million) 10.6.9. REST OF MIDDLE EAST & AFRICA 10.6.9.1. Rest of Middle East & Africa: Market Size and Forecast, By Type, 2023 – 2033 ($ Million) 10.6.9.2. Rest of Middle East & Africa: Market Size and Forecast, By Diagnostic Test, 2023 – 2033 ($ Million) 10.6.9.3. Rest of Middle East & Africa: Market Size and Forecast, By End User, 2023 – 2033 ($ Million) CHAPTER 12. Competitive Landscape 12.1. Competitior Benchmarking 2023 12.2. Market Share Analysis 12.3. Key Developments Analysis By Top 5 Companies 12.4. Market Share Acquisition Strategies: Analysis of Key Approaches Employed by Top Players CHAPTER 13. Company Profiles 13.1. F. Hoffmann-La Roche 13.1.1. Business Overview 13.1.2. Financial Analysis 13.1.2.1. Business Segment Revenue, 2020, 2021, 2022, $ Million 13.1.2.2. Geographic Revenue Mix, 2022 (% Share) 13.1.3. Product Portfolio 13.1.4. Recent Development and Strategies Adopted 13.1.5. SWOT Analysis 13.2. Bristol-Myers Squibb 13.3. AstraZeneca PLC 13.4. Corium Inc 13.5. Eisai Co. Ltd 13.6. Biogen Inc 13.7. Johnson & Johnson 13.8. Eli Lilly and Company 13.9. Lupin Limited 13.10. AbbVie Inc
Connect to Analyst
Research Methodology
Our Most Viewed Report and gain instant expertise
COVID-19 Diagnostics Market Analysis and Global Forecast 2023-2033
COVID-19 Diagnostics Market Research Report: Information By Product (PCR Kits, POC Test, Immunoassay Test, Others), By Technology (Molecular, Immunoassay, Others), By End-User (Hospitals, Diagnostic Labs, Physician’s office and urgent care clinics, Others), and by Region — Forecast till 2033
Page: 160
Desiccant Air Breathers market Analysis and Global Forecast 2023 – 2033
Desiccant Air Breathers Market Research Report: Information By Silica Content By Working Environment (Disposable Stationary Application, Limited Space Application, High Humidity / High Dust Application, Extreme Environment Application, High Vibration Application, Heavy Duty Application, Caustic Fumes/Gaseous Application)
Press Release :https://evolvebi.com/desiccant-air-breathers-market-is-estimated-to-record-a-cagr-of-around-5-58-during-the-forecast-period-2/
Global Endometriosis Treatment Market Analysis and Global Forecast 2024-2034
Global Endometriosis Treatment Market Research Report: Information By Drug Type (Progestin, Gonadotropins Releasing Hormone Agonists, Oral Contraceptive Pills, Non-Steroidal Anti-Inflammatory Drugs, and Others) By Treatment Type (Pain Management and Hormonal Therapies), By Distribution Channel (Hospital Pharmacies, E-Pharmacies, Retail Pharmacies, and Others), and by Region — Forecast till 2034
Page: 160
Home health care products Market Analysis and Global Forecast 2023-2033
Home health care products Market Research Report: By Product (Testing, Screening and Monitoring Products, Blood Glucose Monitors, Blood Pressure Monitors, Pulse Oximeters, Peak Flow Meters, Heart Rate Monitors, Fetal Monitoring Devices, HIV Test Kits, Home Sleep Testing Devices, Others), By Service (Skilled Nursing Services, Rehabilitation Therapy Services, Hospice and Palliative Care Services, Unskilled Care Services, Respiratory Therapy Services, Infusion Therapy Services, Others), By Indication (Cardiovascular Disorders and Hypertension, and by Region — Forecast till 2033
